Eli Lilly’s New $299 Month-Long GLP‑1 Injector Shows Why It’s Winning the Weight‑Loss Race

The drugmaker is introducing a new, more convenient way to inject its blockbuster obesity drug, Zepbound.

BY LEILA SHERIDAN, NEWS WRITER

Photos: Getty Images; Wikimedia Commons

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this year, Lilly has projected roughly 25 percent growth, underscoring just how dramatically the balance of power has shifted in the booming GLP-1 market.

Lilly’s momentum isn’t just about its successful clinical results, though. It’s also about the company’s constant iteration and development processes. 

Today, the drugmaker unveiled a new, month-long injectable device for Zepbound designed to make the treatment more convenient, according to a statement. Instead of using a single-dose autoinjector each week, patients will now be able to store a month’s worth of medication in one pen. The move reduces the number of devices patients must manage and simplifies the treatment routine.

Until now, most Zepbound users relied on weekly, single-dose autoinjector pens. Others used single-dose vials that require drawing the medication into a syringe before self-injection, CNBC reported. The new multi-dose device—called the KwikPen—streamlines that process, eliminating repeated packaging and preparation.

How Canva Became the Power Player in the AI Design Wars

Zepbound has seen explosive demand since its late-2023 launch. Unlike Novo Nordisk’s semaglutide-based drugs Ozempic and Wegovy, Zepbound uses tirzepatide, an active ingredient that has delivered stronger weight-loss results in clinical trials. That performance edge has helped Lilly capture significant market share, according to CNBC. 

In the company’s fourth quarter, Lilly reported $4.2 billion in U.S. revenue, up 122 percent year over year. The surge has played a major role in Lilly surpassing Novo in the weight-loss category.

Another driver of that growth is LillyDirect, the company’s direct-to-consumer digital health platform. The service connects patients with independent telehealth providers for consultations and offers home delivery of medications through partners like Amazon Pharmacy and Truepill. The platform reduces friction in accessing obesity treatments, particularly for cash-paying patients.

© Inc.com